Nasdaq:US$9.58 (+0.00) | HKEX:HK$16.36 (-0.66) | AIM:£1.55 (-0.04)
Search Result
Previous Article   |   Next Article
Scientific Publications | 3 Nov 2021

NANETS 2021: Interim Analysis Results of Surufatinib in US Patients with Neuroendocrine Tumors